Immuneering Corporation is developing novel small molecules for cyclical inhibition of MEK targets, but they are still in early development. Their first developmental project, IMM-1-104, has shown ...
In the split second that is needed to view a stop sign and react to it, our brain navigates a complex process that transitions seamlessly from perception to action control. This ability to halt or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results